Product Data Sheet

Framycetin sulfate

Cat. No.: HY-17624A CAS No.: 4146-30-9

Molecular Formula: C₂₃H₅₂N₆O₂₅S₃

Molecular Weight: 908.88

Target: Bacterial; Antibiotic
Pathway: Anti-infection

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro H₂O: 250 mg/mL (275.06 mM; Need ultrasonic)

DMSO: < 1 mg/mL (ultrasonic; warming; heat to 60°C) (insoluble or slightly soluble)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|-----------|------------|
| | 1 mM | 1.1003 mL | 5.5013 mL | 11.0026 mL |
| | 5 mM | 0.2201 mL | 1.1003 mL | 2.2005 mL |
| | 10 mM | 0.1100 mL | 0.5501 mL | 1.1003 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 50 mg/mL (55.01 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Pramycetin sulfate (Neomycin B sulfate), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a K_i of 35 μ M. Framycetin sulfate competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin sulfate inhibits hammerhead ribozyme with a K_i of 13.5 μ M. Framycetin sulfate, a 5"-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections^{[1][2]}.

| | site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections $^{[1][2]}$. |
|---------------------------|--|
| IC ₅₀ & Target | Aminoglycoside |
| In Vitro | The inhibition of RNase P RNA cleavage by Framycetin sulfate (Neomycin Bsulfate; Fradiomycin Bsulfate) is sensitive to pH and an increase in pH suppresses the inhibition in other systems ^[1] . ?Framycetin sulfate targets the bacterial and human ribosome and affect translation. 5"-azido neomycin B and Framycetin sulfate selectively inhibit production of the mature miRNA, boosts a downstream protein, and inhibits invasion in HCC cell line ^[2] . ?Framycetin sulfate binds to a structural rather than a sequence motif of the RNA. Its primary cognate target is the decoding |

site of the 16S rRNA, but it also binds to the Rev-responsive element in HIV-1, group I introns, and the hammerhead ribozyme, and thus inhibits their biological function $^{[3]}$.

?Framycetin sulfate induces misreading of the genetic code during translation and inhibits several ribozymes. The ribosomal target site is the 16 S rRNA 1400 to 1500 region^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. N E Mikkelsen, et al. Inhibition of RNase P RNA Cleavage by Aminoglycosides. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6155-60.

[2]. Childs-Disney JL, et al. Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma. ACS Chem Biol. 2016 Feb 19;11(2):375-80.

[3]. Stampfl S, et al. Monovalent ion dependence of neomycin B binding to an RNA aptamer characterized by spectroscopic methods. Chembiochem. 2007 Jul 9;8(10):1137-45

[4]. Hoch I, et al. Antibiotic inhibition of RNA catalysis: neomycin B binds to the catalytic core of the td group I intron displacing essential metal ions. J Mol Biol. 1998 Sep 25;282(3):557-69.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com